Sublime
An inspiration engine for ideas
AI-driven design → build → test → learn loops are changing synthetic biology.
CLASSIC compresses gene-circuit design into Golden-Gate pools + nanopore barcodes + Illumina -> reads map 10^5 circuits in one go.
Train on just 7 % of that data and an MLP predicts behavior for 3.4 billion logic ... See more
At first I didn't realize how big this was, until I read the fine print: TLDR with the insights baked in:
OpenAI has developed a novel language model called GPT-4b micro, specifically designed for protein engineering in collaboration with Retro Biosciences, a longevity research company backed by Sam Altman's $180 millio... See more
David Shapiro ⏩x.cominfect cells (see
Ed Regis • Regenesis: How Synthetic Biology Will Reinvent Nature and Ourselves
News: LabGenius' (@labgeni_us) AI-Driven Antibody Discovery Platform Reimagining T-cell Engager Optimisation
#biopharmatrend #biotech
https://t.co/UmOr43FlWc... See more
Oxytricha has 100 million truly tiny chromosomes, each harboring just a single gene.
Thomas R. Cech • The Catalyst: RNA and the Quest to Unlock Life's Deepest Secrets
Two quiet revolutions: reading/writing DNA. The ability to read DNA has greatly exceeded Moore's Law. Your genome can now be sequenced for $100 (which used to cost billions only 25 years ago).
Bryan Johnson • Fireside Chat: A Plan for Humanity with Bryan Johnson
The Gene/Cell Thx origin story & the years it took
*Kymriah methods came from Upenn
*Abecma was licensed from NIH
*Tecartus came from NCI/Sourasky Center/Israel’s Weizmann
*Yescarta licensed to Kite from Sourasky Medical Center & Cabaret Biotech
___LINEBREA... See more
Biotech
Packy McCormick • 3 cards
"Teplizumab had survived 2 failed trials, the disappearance of 4 companies, and a touch and go debate over a prevention trial at NIH, and somehow, it was back on the clock 20 years after its creation"
Great written history of Teplizumab's complicated and unlikely 30-year path from conception to patients
__... See more
Professor Oakx.com